Board Change • Jun 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 1 highly experienced director. Independent Director Lingxiao Mao was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • May 30
Nanjing Hicin Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2025 Nanjing Hicin Pharmaceutical Co., Ltd. announced at annual general meeting held on May 27, 2026, the shareholders approved Cash dividend/10 shares (tax included): CNY 1.00000000 for the year 2025. Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.14 (vs CN¥0.13 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.14 (up from CN¥0.13 in 1Q 2025). Revenue: CN¥160.3m (up 12% from 1Q 2025). Net income: CN¥17.4m (up 16% from 1Q 2025). Profit margin: 11% (in line with 1Q 2025). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has increased by 19% per year, which means it is tracking significantly ahead of earnings growth. New Risk • Apr 25
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 43% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 32% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Announcement • Apr 25
Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2026 Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 27, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Announcement • Mar 31
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 Announcement • Dec 31
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Reported Earnings • Oct 23
Third quarter 2025 earnings released: EPS: CN¥0.029 (vs CN¥0.028 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.029 (up from CN¥0.028 in 3Q 2024). Revenue: CN¥163.0m (up 32% from 3Q 2024). Net income: CN¥3.52m (up 4.2% from 3Q 2024). Profit margin: 2.2% (down from 2.7% in 3Q 2024). Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 27% per year, which means it is well ahead of earnings. Announcement • Sep 30
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 23, 2025 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 23, 2025 Reported Earnings • Aug 26
Second quarter 2025 earnings released: EPS: CN¥0.12 (vs CN¥0.095 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.12 (up from CN¥0.095 in 2Q 2024). Revenue: CN¥165.9m (up 26% from 2Q 2024). Net income: CN¥14.1m (up 24% from 2Q 2024). Profit margin: 8.5% (in line with 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance. Announcement • Jul 02
Nanjing Hicin Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 23, 2025 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 23, 2025 Declared Dividend • Jun 02
Dividend increased to CN¥0.10 Dividend of CN¥0.10 is 100% higher than last year. Ex-date: 9th June 2025 Payment date: 9th June 2025 Dividend yield will be 0.4%, which is lower than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (29% earnings payout ratio) and cash flows (53% cash payout ratio). The dividend has decreased over the past 86 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 68% to shift the payout ratio to a potentially unsustainable range, which is more than the 15% EPS decline seen over the last 5 years. Announcement • May 30
Nanjing Hicin Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2024 Nanjing Hicin Pharmaceutical Co., Ltd. at its AGM held on May 28, 2025 approved cash dividend of CNY 1.00 per share (tax included) for the year 2024. New Risk • May 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥23.20, the stock trades at a trailing P/E ratio of 66.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total loss to shareholders of 32% over the past three years. New Risk • Apr 22
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 21% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Announcement • Apr 22
Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2024 Nanjing Hicin Pharmaceutical Co., Ltd. proposed final cash dividend of CNY 1.00000000 per 10 shares (tax included) for 2024. Reported Earnings • Apr 21
Full year 2024 earnings released: EPS: CN¥0.34 (vs CN¥0.30 in FY 2023) Full year 2024 results: EPS: CN¥0.34 (up from CN¥0.30 in FY 2023). Revenue: CN¥504.4m (down 2.6% from FY 2023). Net income: CN¥40.2m (up 11% from FY 2023). Profit margin: 8.0% (up from 7.0% in FY 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Announcement • Apr 21
Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2025 Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2025, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥16.41, the stock trades at a trailing P/E ratio of 46.9x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total loss to shareholders of 65% over the past three years. Announcement • Mar 31
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 21, 2025 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 21, 2025 Announcement • Dec 31
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 21, 2025 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 21, 2025 Reported Earnings • Oct 27
Third quarter 2024 earnings released: EPS: CN¥0.028 (vs CN¥0.025 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.028 (up from CN¥0.025 in 3Q 2023). Revenue: CN¥124.0m (up 6.5% from 3Q 2023). Net income: CN¥3.38m (up 15% from 3Q 2023). Profit margin: 2.7% (up from 2.5% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance. Board Change • Oct 24
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Lingxiao Mao was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Announcement • Sep 30
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Valuation Update With 7 Day Price Move • Sep 30
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥23.21, the stock trades at a trailing P/E ratio of 67x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 43% over the past three years. Valuation Update With 7 Day Price Move • Aug 29
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to CN¥23.64, the stock trades at a trailing P/E ratio of 75.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total returns to shareholders of 45% over the past three years. New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 1.8% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.6% average weekly change). Valuation Update With 7 Day Price Move • Aug 15
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥19.62, the stock trades at a trailing P/E ratio of 62.9x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total returns to shareholders of 15% over the past three years. Announcement • Jun 29
Nanjing Hicin Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 23, 2024 Announcement • Apr 27
Nanjing Hicin Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2023 Nanjing Hicin Pharmaceutical Co., Ltd. proposed final cash dividend/10 shares (tax included) of CNY 0.50000000 for 2023. Announcement • Apr 26
Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024 Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 15, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Nanjing, Jiangsu China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.11 (vs CN¥0.10 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.11 (up from CN¥0.10 in 1Q 2023). Revenue: CN¥104.6m (down 11% from 1Q 2023). Net income: CN¥13.4m (up 9.4% from 1Q 2023). Profit margin: 13% (up from 10% in 1Q 2023). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥14.37, the stock trades at a trailing P/E ratio of 49.6x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 23% over the past three years. Announcement • Mar 30
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 25, 2024 Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥17.29, the stock trades at a trailing P/E ratio of 59.6x. Average trailing P/E is 26x in the Pharmaceuticals industry in China. Total loss to shareholders of 7.3% over the past three years. Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥17.40, the stock trades at a trailing P/E ratio of 60x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total returns to shareholders of 1.5% over the past three years. Announcement • Dec 29
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 25, 2024 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 25, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.025 (vs CN¥0.02 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.025 (up from CN¥0.02 in 3Q 2022). Revenue: CN¥116.4m (up 4.3% from 3Q 2022). Net income: CN¥2.95m (up 25% from 3Q 2022). Profit margin: 2.5% (up from 2.1% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year and the company’s share price has also increased by 1% per year. New Risk • Oct 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (22% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (6.6% net profit margin). Announcement • Sep 30
Nanjing Hicin Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 27, 2023 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results on Oct 27, 2023 Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.061 (vs CN¥0.043 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.061 (up from CN¥0.043 in 2Q 2022). Revenue: CN¥144.3m (up 23% from 2Q 2022). Net income: CN¥7.26m (up 42% from 2Q 2022). Profit margin: 5.0% (up from 4.4% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥21.02, the stock trades at a trailing P/E ratio of 78.7x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total loss to shareholders of 29% over the past three years. Announcement • Jul 01
Nanjing Hicin Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report first half, 2023 results on Aug 23, 2023 Reported Earnings • Apr 26
Full year 2022 earnings released: EPS: CN¥0.27 (vs CN¥2.38 in FY 2021) Full year 2022 results: EPS: CN¥0.27 (down from CN¥2.38 in FY 2021). Revenue: CN¥526.5m (down 9.0% from FY 2021). Net income: CN¥32.4m (down 89% from FY 2021). Profit margin: 6.2% (down from 49% in FY 2021). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥29.40, the stock trades at a trailing P/E ratio of 12.7x. Average trailing P/E is 34x in the Pharmaceuticals industry in China. Total returns to shareholders of 7.0% over the past three years. Valuation Update With 7 Day Price Move • Dec 08
Investor sentiment improved over the past week After last week's 33% share price gain to CN¥36.99, the stock trades at a trailing P/E ratio of 16x. Average trailing P/E is 38x in the Pharmaceuticals industry in China. Total returns to shareholders of 40% over the past three years. Valuation Update With 7 Day Price Move • Nov 10
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥30.72, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total returns to shareholders of 2.8% over the past three years. Reported Earnings • Oct 26
Third quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.059 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.02 (down from CN¥0.059 in 3Q 2021). Revenue: CN¥111.6m (down 18% from 3Q 2021). Net income: CN¥2.36m (down 67% from 3Q 2021). Profit margin: 2.1% (down from 5.2% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.043 (vs CN¥0.064 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.043 (down from CN¥0.064 in 2Q 2021). Revenue: CN¥117.0m (down 24% from 2Q 2021). Net income: CN¥5.10m (down 33% from 2Q 2021). Profit margin: 4.4% (down from 4.9% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥27.36, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 7.4% over the past three years. Announcement • Jul 19
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Management Changes Nanjing Hicin Pharmaceutical Co., Ltd. at the extraordinary general meeting held on July 15, 2022 approved Cao Xichen as non-independent directors and Zhu Liye as non-employee supervisors. Announcement • Jun 14
Nanjing Hicin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 400 million in funding Nanjing Hicin Pharmaceutical Co., Ltd. announced a private placement of not more than 36,000,000 A shares for gross proceeds not more than CNY 400,000,000 on June 2022. The issuance price of shares must not be lower than 80% of the average trading price of the company's stock in the 20 trading days prior to the pricing benchmark date. The transaction will include participation from not more than 35 investors. The transaction has been approved in the 21st session of the 3rd board of director meeting. The transaction is still subject to approval by the company's general meeting of shareholders, Shenzhen Stock Exchange and China Securities Regulatory Commission. Valuation Update With 7 Day Price Move • May 30
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥31.50, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total returns to shareholders of 40% over the past three years. Announcement • May 20
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Cash Dividend on A Shares for the Year 2021, Payable on May 25, 2022 Nanjing Hicin Pharmaceutical Co., Ltd. announced cash dividend on A shares (tax included) of CNY 2.5000000 per 10 shares for the year 2021. Record date is May 24, 2022. Ex-date is May 25, 2022. The dividend will be payable on May 25, 2022. Announcement • May 19
Nanjing Hicin Pharmaceutical Approves Profit Distribution for 2021 Nanjing Hicin Pharmaceutical Co., Ltd. at its Annual General Meeting held on 16 May 2022 announced profit distribution of CNY 2.5000000 for the year 2021. Valuation Update With 7 Day Price Move • May 07
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥41.34, the stock trades at a trailing P/E ratio of 17.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 69% over the past three years. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS misses analyst expectations First quarter 2022 results: EPS: CN¥0.10 (down from CN¥0.11 in 1Q 2021). Revenue: CN¥150.6m (down 7.2% from 1Q 2021). Net income: CN¥12.6m (down 6.6% from 1Q 2021). Profit margin: 8.4% (up from 8.3% in 1Q 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 5.8%. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. No highly experienced directors. Independent Director Ming Zhao is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Announcement • Apr 24
Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2022 Nanjing Hicin Pharmaceutical Co., Ltd., Annual General Meeting, May 16, 2022, at 14:00 China Standard Time. Agenda: To consider 2021 work report of the board of directors; to consider 2021 work report of the supervisory committee; to consider 2021 special report on the deposit and use of raised funds; to consider 2021 profit distribution plan; to consider Reappointment of 2022 audit firm; to consider 2022 remuneration plan for directors and supervisors; and to consider other matter also. Announcement • Apr 23
Nanjing Hicin Pharmaceutical Proposes Profit Distribution for 2021 Nanjing Hicin Pharmaceutical Co., Ltd. announced profit distribution proposal for 2021 of CNY 2.5000000 for the year 2021. Reported Earnings • Oct 26
Third quarter 2021 earnings released: EPS CN¥0.059 (vs CN¥0.099 in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥136.6m (down 21% from 3Q 2020). Net income: CN¥7.10m (down 40% from 3Q 2020). Profit margin: 5.2% (down from 6.9% in 3Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 04
Second quarter 2021 earnings released: EPS CN¥0.064 (vs CN¥0.16 in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥154.7m (down 26% from 2Q 2020). Net income: CN¥7.63m (down 61% from 2Q 2020). Profit margin: 4.9% (down from 9.2% in 2Q 2020). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 16% per year whereas the company’s share price has fallen by 17% per year. Upcoming Dividend • May 06
Upcoming dividend of CN¥0.13 per share Eligible shareholders must have bought the stock before 13 May 2021. Payment date: 13 May 2021. Trailing yield: 0.6%. Lower than top quartile of Chinese dividend payers (1.9%). Lower than average of industry peers (1.0%). Announcement • May 02
Nanjing Hicin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 13, 2021 Nanjing Hicin Pharmaceutical Co., Ltd. announced final cash dividend on A shares per ten shares (tax included) of CNY 1.25000000 for the year 2020, Payable May 13, 2021. Record date is May 12, 2021. Ex-date is May 13, 2021. Reported Earnings • Apr 08
First quarter 2021 earnings released: EPS CN¥0.11 (vs CN¥0.14 in 1Q 2020) The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥162.2m (down 2.4% from 1Q 2020). Net income: CN¥13.5m (down 21% from 1Q 2020). Profit margin: 8.3% (down from 10% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥20.66, the stock is trading at a trailing P/E ratio of 36.4x, up from the previous P/E ratio of 30.5x. This compares to an average P/E of 32x in the Pharmaceuticals industry in China. Total return to shareholders over the past three years is a loss of 23%. Valuation Update With 7 Day Price Move • Jan 13
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥16.99, the stock is trading at a trailing P/E ratio of 29.9x, down from the previous P/E ratio of 35.5x. This compares to an average P/E of 32x in the Pharmaceuticals industry in China. Total return to shareholders over the past three years is a loss of 31%. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥18.45 The company is down 32% from its price of CN¥27.13 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: CN¥22.55 The company is down 17% from its price of CN¥27.19 on 23 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Nov 30
New 90-day low: CN¥24.11 The company is down 15% from its price of CN¥28.28 on 01 September 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also down 15% over the same period. Reported Earnings • Oct 30
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥68.1m, down 31% from the prior year. Total revenue was CN¥787.9m over the last 12 months, down 9.6% from the prior year. Is New 90 Day High Low • Oct 30
New 90-day low: CN¥24.99 The company is down 23% from its price of CN¥32.44 on 31 July 2020. The Chinese market is down 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 9.0% over the same period. Announcement • Jul 23
Nanjing Hicin Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020 Nanjing Hicin Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020